2003

Dr. James Drake, Inventor of Medafor's MPH™ Technology, Named "Innovator of the Year"
Minneapolis, Minn., August 20, 2003 - Medafor, Inc., announced today that Dr. James Drake, Medafor's Chief Scientist and the inventor and patent holder of Medafor's MPH (Microporous Polysaccharide Hemospheres) hemostatic technology, has been named an Innovator of the Year by Finance and Commerce Daily Business Newspaper, a publication of Dolan Media, Minneapolis. READ FULL STORY.

Medafor, Inc., Relocates to Larger Facility in Brooklyn Center, Minnesota
Minneapolis, Minn., July 10, 2003 -- Medafor, Inc., announced today that it has relocated its corporate headquarters to Brooklyn Center, a northern suburb of Minneapolis. The move accomplished a number of enhancements to the company's operations and customer service capabilities. READ FULL STORY.

SIR 2003
Medafor will introduce its innovative MPatcH hemostatic bandage at the Society of Interventional Radiology in Salt Lake City this month. The MPatcH is designed to provide virtually instant hemostasis and closure at vascular access sites subsequent to diagnostic and interventional procedures. The MPatcH and its patented component MPH hemostatic agent will be demonstrated each day, throughout the duration of the conference, at the Medafor booth, number 1409.

2002

Arista™AH, Medafor's Surgical Hemostatic Technology, Receives Approval for European Market
Minneapolis, Minn., September 19, 2002 - Medafor, Inc., announced today that its breakthrough surgical hemostat, Arista™ AH, has received CE mark for intra-operative surgical applications. The Company will now actively market to a range of surgical indications in Europe through its recently opened international service center in Munich, Germany. READ FULL STORY.

Department Paramedics Begin Using Blood Clotting Agent to Control Profuse Bleeding
Saint Paul, Minn., August 1, 2002 - The Saint Paul Department of Fire and Safety Services Paramedic Units will now use TraumaDEX™ to assist in wound management with severe bleeding in the pre-hospital setting. READ FULL STORY.

FDA Approves Medafor's MPH™ for Management of Surgical and Vascular Access Site Bleeding
Minneapolis, Minn., July 12, 2002 - Medafor, Inc., has received regulatory clearance from the Food and Drug Administration to market its MPH™ (Microporous Polysaccharide Hemospheres) technology for use in sugical and chronic care indications.

Medafor Signs Distribution Agreement with Abbott Animal Health, a Division of Abbott Laboratories
Minneapolis, Minn., June 10, 2002 - Medafor, Inc., a market innovator in the development of advanced hemostasis and wound management technology, announced today that it has signed an exclusive, multi-year agreement with Abbott Laboratories for the distribution of HemaBlock™ "Stop the Bleed" to the veterinary market in the United States and worldwide. READ FULL STORY.

Medafor Signs Distribution Agreement with Emergency Medical Products (EMP)
Minneapolis, Minn., February 12, 2002 - Medafor, Inc., a market innovator in the development of advanced hemostasis and wound management technology, announced today that it has signed an agreement with Emergency Medical Products, Inc., a national leader in the distribution of emergency medical equipment and supplies. READ FULL STORY.

2001

FDA Approves Medafor's Unique Hemostatic Technology
Minneapolis, Minn., December 2001 - Medafor, Inc., announced today that the company has received regulatory clearance from the Food and Drug Administration (FDA) to market its breakthrough technology as a topical hemostat for the local management of bleeding wounds. READ FULL STORY.

Medafor, Inc., Appoints Price Waterhouse Coopers to Support Operations
Minneapolis, Minn., August 2001 - Medafor, Inc., is pleased to announce that an agreement has been reached with PricewaterhouseCoopers to provide independent financial services in support of the company's escalating market position.

Medafor, Inc., Adds Two Management Team Members
Minneapolis, Minn., June 7, 2001 - Medafor, Inc., is pleased to announce the addition of two members to its management team. READ FULL STORY.

Hemadex Technology Studies Presented at NATA Symposium
Minneapolis, Minn., April 2001 - Medafor, Inc., is proud to announce that its MPH™ (Microporous Polysaccharide Hemospheres) technology was the subject of two studies presented at the Network for Advancement of Transfusion Alternatives (NATA) Symposium last month in Berlin. READ FULL STORY.

2000

Medafor, Inc., Announces the Formation of Its Medical Advisory Board
Minneapolis, Minn., June 2000 - Medafor, Inc., announces the establishment of its Medical Advisory Board of leading experts in hematology, wound management, trauma surgery, dermatology, vascular surgery and medical device regulations. READ FULL STORY.

Patent Awarded to Medafor, Inc., for Topically Applied Blood Clotting Methods
Minneapolis, Minn., May 2000 - Recognizing the distinctive qualities of Medafor's innovative technology, the U.S. Patent Office has issued protection covering 31 method claims for producing hemostasis using microporous particles. READ FULL STORY.